Evaluation of Predictors of Biochemical Recurrence in Prostate Cancer Patients, as Detected by Ga-PSMA PET/CT.

Objectives: To explore the existence of new predictors of the Ga-Prostate-Specific Membrane Antigen (PSMA) PET/CT detection rate at biochemical recurrence (BCR) and to determine the detection rate of Ga-PSMA PET/CT dependent of prostate-specific antigen (PSA) levels.

Materials And Methods: In total, 189 PCa patients scanned with Ga-PSMA PET/CT for detection of BCR after curatively intended treatment with either radical prostatectomy ( = 153) or radiotherapy ( = 36) were included. Clinicopathological information at the time of diagnosis (PSA, clinical tumor-stage, International Society of Urological Pathology Grade Group and whether Ga-PSMA PET/CT was used for primary staging), treatment (RT/RP and histopathology of the prostatectomies), and pre-PET PSA were collected from medical records.

Avid 68Ga-PSMA Uptake in Periappendicular Abscess.

Ga-prostate-specific membrane antigen (PSMA) PET/CT for primary staging of high-risk prostate cancer revealed increased Ga-PSMA uptake in a known periappendicular abscess in a patient, who had undergone surgical drainage of the abscess 1 month earlier. The case presents another example of Ga-PSMA uptake in a benign infectious and inflammatory condition.

The putative neuropeptide TAFA5 is expressed in the hypothalamic paraventricular nucleus and is regulated by dehydration.

In a search for novel genes involved in the hypothalamic control of body energy homeostasis bioinformatic tools were applied. Analysis of the presence of structural features characteristic for secretory peptides was used as a first step in the identification of novel neuropeptides, and was followed by analysis of expression patterns. The gene product previously named TAFA5 was identified during this process.